BrainChild Bio Receives $300,000 G-Rex® Grant
ScaleReady has proudly announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. This significant funding will assist in the swift development and commercial readiness of BCB-276, the company’s lead autologous CAR-T therapy. It is aimed specifically at addressing diffuse intrinsic pontine glioma (DIPG), a challenging pediatric brain tumor that currently lacks effective treatment options.
Advancements in Cancer Therapy
BrainChild Bio plans to initiate a multi-center Phase 2 pivotal clinical trial in the near future, focusing on young patients suffering from DIPG. Dr. Michael Jensen, Chief Scientific Officer at BrainChild Bio, expressed gratitude, noting how the G-Rex has been pivotal in their clinical CAR-T manufacturing journey, appreciating both the grant and the technical support provided by ScaleReady.
Support from ScaleReady
John Wilson, CEO of Wilson Wolf Manufacturing Corporation and co-inventor of G-Rex, highlighted the inspiring work of Dr. Jensen's team over the years. He stated, "It is our honor to expedite BrainChild's innovative treatment for brain tumors, aligning perfectly with our mission to provide hope to cancer patients everywhere." This collaboration stands as a testament to the importance of partnerships in advancing healthcare.
Manufacturing Innovations for CAR-T Therapy
The G-Rex Grant will enable BrainChild Bio to enhance their CAR-T cell manufacturing process. This enhancement is essential as they prepare for their pivotal clinical trial. The grant offers an opportunity to streamline processes, improve consistency, and heighten flexibility through the G-Rex platform. Additionally, the possibility of using CellReady's standardized CAR-T cell process will further bolster efficiency by utilizing a closed-end-to-end manufacturing workflow.
ScaleReady's G-Rex Grant Program
ScaleReady's G-Rex Grant Program is a bold initiative with an impressive total of $20 million allocated for cell and gene-modified cell therapy (CGT) development. It aims to award various grants, supporting innovators and researchers in advancing their groundbreaking solutions. Each grant recipient benefits from a consortium of partners, all possessing specialized knowledge in GMP manufacturing, quality assurance, regulatory affairs, and other crucial areas of CGT.
Positive Outcomes for Cancer Patients
BrainChild Bio is committed to improving outcomes for children facing malignancies. The innovative CAR-T therapy that BrainChild is developing demonstrates promise not only in addressing DIPG but potentially in other pediatric cancers as well. The advances made through the G-Rex Grant can help ensure that therapies are available sooner for those who need them most.
About ScaleReady
ScaleReady specializes in providing advanced manufacturing solutions focused on serving the cell and gene-modified cell therapy field. Their G-Rex-centric platform emphasizes practicality and affordability, enabling organizations to develop drug products that can change lives. With over 800 institutions utilizing their technology, they are a vital player in the CGT landscape.
About Wilson Wolf Manufacturing
Wilson Wolf Manufacturing has devoted itself to simplifying cell and gene-modified cell therapy through its innovative G-Rex technology. Their mission tightly revolves around generating hope for cancer patients, showcasing their impact on research, process development, and manufacturing.
About Bio-Techne Corporation
Bio-Techne Corporation, traded on NASDAQ as TECH, serves the life sciences community by offering innovative tools and bioactive reagents. Partnering with Wilson Wolf, they provide tailored products to optimize G-Rex® Bioreactors, enhancing CGT applications.
About BrainChild Bio
BrainChild Bio is a clinical-stage biotechnology firm dedicated to pediatric health. By utilizing CAR T-cell technology, they aim to transform treatment for central nervous system tumors. Their leading drug candidate, BCB-276, specifically targets the immune checkpoint B7-H3, crucial for treating challenging cancers like DIPG.
Frequently Asked Questions
What is the G-Rex Grant?
The G-Rex Grant is a funding initiative aimed at enhancing cell and gene-modified therapy development, providing financial support and resources to organizations like BrainChild Bio.
What will the grant help BrainChild Bio achieve?
The grant will assist in the process development and optimization of their CAR-T cell manufacturing, specifically preparing for a pivotal clinical trial for DIPG treatment.
Who is involved in the G-Rex Grant Program?
ScaleReady, Wilson Wolf Manufacturing, and other partners contribute expertise and resources to support recipients in advancing their therapeutic solutions.
What is the significance of BCB-276?
BCB-276 is a pioneering CAR-T cell therapy aimed at treating DIPG, a currently incurable pediatric brain tumor. Its development represents a crucial advance in addressing this medical challenge.
How does ScaleReady support organizations?
ScaleReady provides a manufacturing platform and a consortium of partners, offering knowledge and tools to streamline CGT development and commercialization, helping organizations save time and resources.
